Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
26.24
+0.75 (2.94%)
At close: Aug 19, 2026, 4:00 PM EDT
28.68
+2.44 (9.30%)
Pre-market: Aug 20, 2026, 7:34 AM EDT
Ultragenyx Pharmaceutical Employees
Ultragenyx Pharmaceutical had 1,371 employees as of December 31, 2025. The number of employees increased by 77 or 5.95% compared to the previous year.
Employees
1,371
Change (1Y)
77
Growth (1Y)
5.95%
Revenue / Employee
$522,976
Profits / Employee
-$427,425
Market Cap
2.58B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,371 | 77 | 5.95% |
| Dec 31, 2024 | 1,294 | 18 | 1.41% |
| Dec 31, 2023 | 1,276 | -35 | -2.67% |
| Dec 31, 2022 | 1,311 | 192 | 17.16% |
| Dec 31, 2021 | 1,119 | 226 | 25.31% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Ocular Therapeutix | 325 |
| Nuvation Bio | 305 |
| UroGen Pharma | 300 |
| Precigen | 160 |
| Pharvaris | 148 |
| Kodiak Sciences | 141 |
| AtaiBeckley | 99 |
| Mineralys Therapeutics | 76 |
RARE News
- 41 minutes ago - Ultragenyx price target raised to $83 from $81 at Canaccord - TheFly
- 1 hour ago - Ultragenyx price target raised to $46 from $45 at Wells Fargo - TheFly
- 1 hour ago - Ultragenyx price target raised to $58 from $45 at Citi - TheFly
- 14 hours ago - Ultragenyx's gene therapy for rare metabolic disorder secures US FDA nod - Reuters
- 14 hours ago - Ultragenyx announces FDA accelerated approval of Genglycos - TheFly
- 14 hours ago - Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa) - GlobeNewsWire
- 15 days ago - Ultragenyx price target raised to $81 from $79 at Canaccord - TheFly
- 15 days ago - Ultragenyx price target lowered to $45 from $47 at Wells Fargo - TheFly